Compare Quest Diagnostics Inc (DGX) vs GXO Logistics Inc (GXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs GXO Logistics Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while GXO Logistics Inc trades at $46.63 (market cap $5.32B). The key difference: Quest Diagnostics Inc is far larger — about 4.8× GXO Logistics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and GXO Logistics Inc for 28 Days on average.
| DGX | GXO | |
|---|---|---|
Market Cap | $25.48B | $5.32B |
Volume | 941,866 | 1,255,816 |
Sector | Health | Industrials |
52-Week High | $247.45 | $65.59 |
52-Week Low | $173.49 | $44.17 |
Typical Hold Time | 56 Days | 28 Days |
Enterprise Value | $31.23B | $10.67B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
GXO trades at $46.47, up 1.04% with neutral technical indicators and strong analyst support. The company shows improving fundamentals with Q2 2026 revenue of $3.4 billion (up 4% YoY) and three consecutive earnings beats. Recent strategic partnerships with Columbia Sportswear and technology investments in labor management systems position GXO for operational efficiency gains. The stock trades at a P/E of 41.03 and P/S of 0.39, reflecting growth expectations amid modest current profitability.
GXO presents a compelling growth story with 88.9% analyst buy ratings and a $66.67 consensus price target (43% upside). However, margin compression remains a concern as new business wins show lower incremental profitability. The company's expansion in aerospace/defense and European logistics markets provides growth catalysts, but investors should monitor execution on the 6% EBIT margin target and supply chain industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
